12 patents
Utility
Methods of Treating Malignant Lymphoproliferative Disorders
27 Apr 23
Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING-41, are provided.
Francis GILES, Andrew MAZAR
Filed: 3 Nov 22
Utility
Compounds for the Treatment of Myelofibrosis
2 Mar 23
The present invention provides methods of treating myelofibrosis in a patient by administering to the patient a therapeutically effective amount of a 08K-3β inhibitor such as 3-(5-fluorobenzofuran-3-y1)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-y1)pynOle-2,5-dione, or a pharmaceutically acceptable salt thereof, optionally in combination with a therapeutically effective amount of a JAK inhibitor such as ruxolitinib, or a pharmaceutically acceptable salt thereof.
Francis J. GILES, Andrew MAZAR
Filed: 23 Dec 20
Utility
Methods of treating malignant lymphoproliferative disorders
29 Nov 22
Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING-41, are provided.
Francis Giles, Andrew Mazar
Filed: 5 Jun 19
Utility
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
3 Nov 22
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin ZHANG
Filed: 1 Jul 22
Utility
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
9 Aug 22
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl) pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin Zhang
Filed: 16 Oct 18
Utility
Immunohistochemical Staining for GSK-3
3 Feb 22
Methods of using immunohistochemical staining to identify cells expressing GSK-3 and use of such methods in treating disease are disclosed.
Andrey UGOLKOV
Filed: 12 Dec 19
Utility
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
13 Jan 22
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin ZHANG
Filed: 24 Sep 21
Utility
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
5 Oct 21
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin Zhang
Filed: 10 Aug 18
Utility
Methods of Treating Malignant Lymphoproliferative Disorders
29 Jul 21
Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING41, are provided.
Francis GILES, Andrew MAZAR
Filed: 5 Jun 19
Utility
Treatment of Idiopathic Pulmonary Fibrosis with Glycogen Synthase Kinase 3 Form Beta Inhibitors
15 Jul 21
Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form β; GSK 3β) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models.
Torry A. TUCKER, Steven IDELL
Filed: 16 May 19
Utility
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
29 Jul 20
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo [4,5-f]indol-7-yl) pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin ZHANG
Filed: 15 Oct 18
Utility
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
15 Jul 20
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.
Yamin ZHANG
Filed: 9 Aug 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first